Posttherapy [18F]FDOPA PET Findings in an Anaplastic Pleomorphic Xanthoastrocytoma With a BRAF V600E Mutation.
This report describes a 10-year-old boy with BRAF V600E-mutant anaplastic pleomorphic xanthoastrocytoma treated with combined BRAF/MEK inhibition, in whom posttherapy [18F]FDOPA PET provided metabolic information that preceded and complemented conventional imaging.
Open original publication →What the AI sees
This report describes a 10-year-old boy with BRAF V600E-mutant anaplastic pleomorphic xanthoastrocytoma treated with combined BRAF/MEK inhibition, in whom posttherapy [18F]FDOPA PET provided metabolic information that preceded and complemented conventional imaging.
Research significance
The case provides preliminary evidence that [18F]FDOPA PET may help monitor targeted therapy in BRAF V600E-mutant pediatric APXA; it remains an inference—not established by this record—that earlier metabolic changes could improve treatment-response assessment or therapeutic decision-making.
Source abstract
Anaplastic pleomorphic xanthoastrocytoma (APXA) is a rare pediatric high-grade glioma (pHGG). We report a 10-year-old boy with a left temporal APXA harboring a BRAF V600E mutation, who presented with generalized tonic-clonic seizures 3-4 times weekly, treated with combined BRAF and MEK inhibition. This case illustrates the utility of [18F]FDOPA PET in monitoring targeted therapy, providing metabolic information that preceded and complemented conventional imaging.